OTCMKTS:MATN - Mateon Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.1160 +0.00 (+0.87 %) (As of 01/23/2019 02:39 AM ET)Previous Close$0.1150Today's Range$0.1160 - $0.116052-Week Range$0.05 - $0.3096Volume1,005 shsAverage Volume13,257 shsMarket Capitalization$4.80 millionP/E Ratio-0.22Dividend YieldN/ABeta2.19 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California. Receive MATN News and Ratings via Email Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MATN Previous SymbolNASDAQ:MATN CUSIPN/A Webwww.mateon.com Phone650-635-7000Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05Price-To-Earnings Trailing P/E Ratio-0.22 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-5.80Profitability EPS (Most Recent Fiscal Year)($0.52) Net Income$-13,810,000.00 Net MarginsN/A Return on Equity-4,138.38% Return on Assets-397.10%Miscellaneous Employees5 Outstanding Shares41,420,000Market Cap$4.80 million OptionableNot Optionable Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions What is Mateon Therapeutics' stock symbol? Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN." How were Mateon Therapeutics' earnings last quarter? Mateon Therapeutics Inc (OTCMKTS:MATN) issued its quarterly earnings data on Wednesday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). View Mateon Therapeutics' Earnings History. When is Mateon Therapeutics' next earnings date? Mateon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 15th 2019. View Earnings Estimates for Mateon Therapeutics. What price target have analysts set for MATN? 1 analysts have issued 12-month target prices for Mateon Therapeutics' stock. Their predictions range from $1.00 to $1.00. On average, they expect Mateon Therapeutics' share price to reach $1.00 in the next year. This suggests a possible upside of 762.1% from the stock's current price. View Analyst Price Targets for Mateon Therapeutics. What is the consensus analysts' recommendation for Mateon Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mateon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mateon Therapeutics. Has Mateon Therapeutics been receiving favorable news coverage? News coverage about MATN stock has trended very positive recently, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mateon Therapeutics earned a media sentiment score of 3.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. Who are some of Mateon Therapeutics' key competitors? Some companies that are related to Mateon Therapeutics include Titan Pharmaceuticals (TTNP), aTyr Pharma (LIFE), Windtree Therapeutics (WINT), Mymetics (MYMX), Aevi Genomic Medicine (GNMX), Vaxart (VXRT), TrovaGene (TROV), Genetic Technologies (GENE), Enzon Pharmaceuticals (ENZN), Neuralstem (CUR), Vitro Diagnostics (VODG), Taxus Cardium Pharmaceuticals Group (CRXM), Omni Bio Pharmaceutical (OMBP), AveXis (AVXS) and Osiris Therapeutics (OSIR). Who are Mateon Therapeutics' key executives? Mateon Therapeutics' management team includes the folowing people: Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 61)Mr. Matthew M. Loar, Chief Financial Officer (Age 56)Ms. Shari Annes, Exec. Officer of Investor RelationsDr. Yuval Binur, Exec. VP of FinancialMs. Pamela Ha, Controller How do I buy shares of Mateon Therapeutics? Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mateon Therapeutics' stock price today? One share of MATN stock can currently be purchased for approximately $0.1160. How big of a company is Mateon Therapeutics? Mateon Therapeutics has a market capitalization of $4.80 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Mateon Therapeutics employs 5 workers across the globe. What is Mateon Therapeutics' official website? The official website for Mateon Therapeutics is http://www.mateon.com. How can I contact Mateon Therapeutics? Mateon Therapeutics' mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected] MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 150 (Vote Outperform)Underperform Votes: 137 (Vote Underperform)Total Votes: 287MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/23/2019 by MarketBeat.com StaffFeatured Article: Should You Consider an Index Fund?